Commonwealth Equity Services
JUNO

Commonwealth Equity Services’s Juno Therapeutics, Inc. JUNO Stock Holding History

Commonwealth Equity Services’s Portfolio JUNO Stock Details JUNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-17,540
Closed -$802K – 2832
2017
Q4 		$802K Sell
17,540
-1,010
-5% -$50.4K ﹤0.01% 1362
2017
Q3 		$832K Sell
18,550
-3,735
-17% -$127K 0.01% 1289
2017
Q2 		$666K Buy
22,285
+225
+1% +$5.55K ﹤0.01% 1380
2017
Q1 		$490K Buy
22,060
+500
+2% +$10.7K ﹤0.01% 1517
2016
Q4 		$406K Sell
21,560
-1,278
-6% -$31.3K ﹤0.01% 1537
2016
Q3 		$685K Sell
22,838
-703
-3% -$21.9K 0.01% 1202
2016
Q2 		$905K Buy
23,541
+2,031
+9% +$84.3K 0.01% 1035
2016
Q1 		$819K Buy
21,510
+4,150
+24% +$145K 0.01% 1050
2015
Q4 		$763K Buy
17,360
+1,700
+11% +$84.3K 0.01% 1071
2015
Q3 		$637K Buy
15,660
+6,460
+70% +$283K 0.01% 1117
2015
Q2 		$491K Buy
9,200
+3,150
+52% +$167K ﹤0.01% 1340
2015
Q1 		$367K Buy
+6,050
New +$294K ﹤0.01% 1504

Other funds holding JUNO

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
GT
Glenmede Trust Philadelphia, Pennsylvania $20.4B AUM

Commonwealth Equity Services's JUNO Position: Q1 2018 in Review

Commonwealth Equity Services sold out of Juno Therapeutics, Inc. (JUNO) in Q1 2018, closing a stake of 17,540 shares — an estimated $802K sold.

Commonwealth Equity Services first reported a position in JUNO in Q1 2015 and held it in 12 quarters. The position peaked at $905K in Q2 2016. 2 funds tracked by Wall St. Rank hold JUNO as of Q1 2018.

  • Commonwealth Equity Services reported no remaining Juno Therapeutics, Inc. position as of Q1 2018 after selling out during the quarter.
  • Commonwealth Equity Services sold 17,540 Juno Therapeutics, Inc. shares in Q1 2018, an estimated $802K.
  • Commonwealth Equity Services first reported a position in Juno Therapeutics, Inc. in Q1 2015 and held it in 12 quarters.
  • Commonwealth Equity Services's Juno Therapeutics, Inc. position peaked at $905K in Q2 2016.
  • 2 funds tracked by Wall St. Rank held Juno Therapeutics, Inc. as of Q1 2018.

Based on Commonwealth Equity Services's 13F filing for Q1 2018, filed 14 May 2018.